SGEN
Seattle Genetics Inc
Halal Rating :
Last Price
$228.96
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
Seagen Inc., formerly Seattle Genetics, is a biotechnology company focused on developing and commercializing innovative antibody-based therapies for the treatment of cancer. The company specializes in antibody-drug conjugate (ADC) technology, which enables targeted delivery of drugs to cancer cells. Their main products include ADCETRIS for lymphoma treatment, PADCEV for bladder cancer, and TUKYSA for breast cancer.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2023 | $648.65m | $879.99m | - | - | 0.00% | 0.00% |
| June 30, 2023 | $603.83m | $824.55m | - | - | 0.00% | 0.00% |
| March 31, 2023 | $519.72m | $704.23m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Seattle Genetics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.